|
1
|
Henriksson R, Asklund T and Poulsen HS:
Impact of therapy on quality of life, neurocognitive function and
their correlates in glioblastoma multiforme: a review. J
Neurooncol. 104:639–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nieder C and Mehta MP: Advances in
translational research provide a rationale for clinical
re-evaluation of high-dose radiotherapy for glioblastoma. Med
Hypotheses. 76:410–413. 2011. View Article : Google Scholar
|
|
3
|
Shirai K and Chakravarti A: Towards
personalized therapy for patients with glioblastoma. Expert Rev
Anticancer Ther. 11:1935–1944. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Graeber TG, Osmanian C, Jacks T, Housman
DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of
cells with diminished apoptotic potential in solid tumours. Nature.
379:88–91. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bristow RG and Hill RP: Hypoxia and
metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev
Cancer. 8:180–192. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Collingridge DR, Piepmeier JM, Rockwell S
and Knisely JP: Polarographic measurements of oxygen tension in
human glioma and surrounding peritumoural brain tissue. Radiother
Oncol. 53:127–131. 1999. View Article : Google Scholar
|
|
7
|
Bar EE: Glioblastoma, cancer stem cells
and hypoxia. Brain Pathol. 21:119–129. 2011. View Article : Google Scholar
|
|
8
|
Heddleston JM, Li Z, McLendon RE,
Hjelmeland AB and Rich JN: The hypoxic microenvironment maintains
glioblastoma stem cells and promotes reprogramming towards a cancer
stem cell phenotype. Cell Cycle. 8:3274–3284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McCord AM, Jamal M, Shankavaram UT, Lang
FF, Camphausen K and Tofilon PJ: Physiologic oxygen concentration
enhances the stem-like properties of CD133+ human
glioblastoma cells in vitro. Mol Cancer Res. 7:489–497. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seidel S, Garvalov BK, Wirta V, von
Stechow L, Schänzer A, Meletis K, Wolter M, Sommerlad D, Henze AT,
Nistér M, et al: A hypoxic niche regulates glioblastoma stem cells
through hypoxia inducible factor 2 alpha. Brain. 133:983–995. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kolenda J, Jensen SS, Aaberg-Jessen C,
Christensen K, Andersen C, Brünner N and Kristensen BW: Effects of
hypoxia on expression of a panel of stem cell and chemoresistance
markers in glioblastoma-derived spheroids. J Neurooncol. 103:43–58.
2011. View Article : Google Scholar
|
|
12
|
Vordermark D and Brown JM: Endogenous
markers of tumor hypoxia predictors of clinical radiation
resistance? Strahlenther Onkol. 179:801–811. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bache M, Kappler M, Said HM, Staab A and
Vordermark D: Detection and specific targeting of hypoxic regions
within solid tumors: Current preclinical and clinical strategies.
Curr Med Chem. 15:322–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dahlrot RH, Hermansen SK, Hansen S and
Kristensen BW: What is the clinical value of cancer stem cell
markers in gliomas? Int J Clin Exp Pathol. 6:334–348.
2013.PubMed/NCBI
|
|
15
|
Haar CP, Hebbar P, Wallace GC IV, Das A,
Vandergrift WA III, Smith JA, Giglio P, Patel SJ, Ray SK and Banik
NL: Drug resistance in glioblastoma: a mini review. Neurochem Res.
37:1192–1200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tanaka S, Louis DN, Curry WT, Batchelor TT
and Dietrich J: Diagnostic and therapeutic avenues for
glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 10:14–26.
2013. View Article : Google Scholar
|
|
17
|
Dreyfuss JM, Johnson MD and Park PJ:
Meta-analysis of glioblastoma multiforme versus anaplastic
astrocytoma identifies robust gene markers. Mol Cancer. 8:712009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin F, Zhao L, Zhao HY, Guo SG, Feng J,
Jiang XB, Zhang SL, Wei YJ, Fu R and Zhao JS: Comparison between
cells and cancer stem-like cells isolated from glioblastoma and
astrocytoma on expression of anti-apoptotic and multidrug
resistance-associated protein genes. Neuroscience. 154:541–550.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Casalbore P, Budoni M, Ricci-Vitiani L,
Cenciarelli C, Petrucci G, Milazzo L, Montano N, Tabolacci E, Maira
G, Larocca LM, et al: Tumorigenic potential of olfactory
bulb-derived human adult neural stem cells associates with
activation of TERT and NOTCH1. PLoS One. 4:e44342009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Acquati S, Greco A, Licastro D, Bhagat H,
Ceric D, Rossini Z, Grieve J, Shaked-Rabi M, Henriquez NV, Brandner
S, et al: Epigenetic regulation of survivin by Bmi1 is cell type
specific during corticogenesis and in gliomas. Stem Cells.
31:190–202. 2013. View Article : Google Scholar
|
|
21
|
Guvenc H, Pavlyukov MS, Joshi K, Kurt H,
Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Bhasin
D, et al: Impairment of glioma stem cell survival and growth by a
novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res.
19:631–642. 2013. View Article : Google Scholar
|
|
22
|
Mao XG, Hütt-Cabezas M, Orr BA, Weingart
M, Taylor I, Rajan AK, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G,
et al: LIN28A facilitates the transformation of human neural stem
cells and promotes glioblastoma tumorigenesis through a
pro-invasive genetic program. Oncotarget. 4:1050–1064.
2013.PubMed/NCBI
|
|
23
|
Paul I, Bhattacharya S, Chatterjee A and
Ghosh MK: Current understanding on EGFR and Wnt/β-catenin signaling
in glioma and their possible crosstalk. Genes Cancer. 4:427–446.
2013. View Article : Google Scholar
|
|
24
|
Söling A, Plugge EM, Schmitz M, Weigle B,
Jacob R, Illert J, Holzhausen HJ and Rainov NG: Autoantibodies to
the inhibitor of apoptosis protein survivin in patients with brain
tumors. Int J Oncol. 30:123–128. 2007.
|
|
25
|
Bache M, Kappler M, Wichmann H, Rot S,
Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, et al:
Elevated tumor and serum levels of the hypoxia-associated protein
osteopontin are associated with prognosis for soft tissue sarcoma
patients. BMC Cancer. 10:1322010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Said HM, Hagemann C, Staab A, Stojic J,
Kühnel S, Vince GH, Flentje M, Roosen K and Vordermark D:
Expression patterns of the hypoxia-related genes osteopontin, CA9,
erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in
vivo. Radiother Oncol. 83:398–405. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Søndergaard KL, Hilton DA, Penney M,
Ollerenshaw M and Demaine AG: Expression of hypoxia-inducible
factor 1alpha in tumours of patients with glioblastoma. Neuropathol
Appl Neurobiol. 28:210–217. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou YH, Tan F, Hess KR and Yung WK: The
expression of PAX6, PTEN, vascular endothelial growth factor, and
epidermal growth factor receptor in gliomas: relationship to tumor
grade and survival. Clin Cancer Res. 9:3369–3375. 2003.PubMed/NCBI
|
|
29
|
Nam DH, Park K, Suh YL and Kim JH:
Expression of VEGF and brain specific angiogenesis inhibitor-1 in
glioblastoma: Prognostic significance. Oncol Rep. 11:863–869.
2004.PubMed/NCBI
|
|
30
|
Scrideli CA, Carlotti CG Jr, Mata JF,
Neder L, Machado HR, Oba-Sinjo SM, Rosemberg S, Marie SK and Tone
LG: Prognostic significance of co-overexpression of the
EGFR/IGFBP-2/HIF-2A genes in astrocytomas. J Neurooncol.
83:233–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kajiwara Y, Yamasaki F, Hama S, Yahara K,
Yoshioka H, Sugiyama K, Arita K and Kurisu K: Expression of
survivin in astrocytic tumors: correlation with malignant grade and
prognosis. Cancer. 97:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma YH, Mentlein R, Knerlich F, Kruse ML,
Mehdorn HM and Held-Feindt J: Expression of stem cell markers in
human astrocytomas of different WHO grades. J Neurooncol. 86:31–45.
2008. View Article : Google Scholar
|
|
33
|
Sun G, Wang Y, Sun L, Luo H, Liu N, Fu Z
and You Y: Clinical significance of Hiwi gene expression in
gliomas. Brain Res. 1373:183–188. 2011. View Article : Google Scholar
|
|
34
|
Yoshimoto K, Ma X, Guan Y, Mizoguchi M,
Nakamizo A, Amano T, Hata N, Kuga D and Sasaki T: Expression of
stem cell marker and receptor kinase genes in glioblastoma tissue
quantified by real-time RT-PCR. Brain Tumor Pathol. 28:291–296.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang L, He S, Yuan J, Mao X, Cao Y, Zong
J, Tu Y and Zhang Y: Oncogenic role of SOX9 expression in human
malignant glioma. Med Oncol. 29:3484–3490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Güttler A, Giebler M, Cuno P, Wichmann H,
Kessler J, Ostheimer C, Söling A, Strauss C, Illert J, Kappler M,
et al: Osteopontin and splice variant expression level in human
malignant glioma: radiobiologic effects and prognosis after
radiotherapy. Radiother Oncol. 108:535–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Murat A, Migliavacca E, Gorlia T, Lambiv
WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven
MC, et al: Stem cell-related ‘self-renewal’ signature and high
epidermal growth fact or receptor expression associated with
resistance to concomitant chemoradiotherapy in glioblastoma. J Clin
Oncol. 26:3015–3024. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feng R, Zhou S, Liu Y, Song D, Luan Z, Dai
X, Li Y, Tang N, Wen J and Li L: Sox2 protects neural stem cells
from apoptosis via up-regulating survivin expression. Biochem J.
450:459–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peng XH, Karna P, Cao Z, Jiang BH, Zhou M
and Yang L: Cross-talk between epidermal growth factor receptor and
hypoxia-inducible factor-1alpha signal pathways increases
resistance to apoptosis by up-regulating survivin gene expression.
J Biol Chem. 281:25903–25914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Misra A, Pandey C, Sze SK and Thanabalu T:
Hypoxia activated EGFR signaling induces epithelial to mesenchymal
transition (EMT). PLoS One. 7:e497662012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Korkolopoulou P, Patsouris E,
Konstantinidou AE, Pavlopoulos PM, Kavantzas N, Boviatsis E,
Thymara I, Perdiki M, Thomas-Tsagli E, Angelidakis D, et al:
Hypoxia-inducible factor 1alpha/vascular endothelial growth factor
axis in astrocytomas. Associations with microvessel morphometry,
proliferation and prognosis. Neuropathol Appl Neurobiol.
30:267–278. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Flynn JR, Wang L, Gillespie DL, Stoddard
GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY and
Jensen RL: Hypoxia-regulated protein expression, patient
characteristics, and preoperative imaging as predictors of survival
in adults with glioblastoma multiforme. Cancer. 113:1032–1042.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sathornsumetee S, Cao Y, Marcello JE,
Herndon JE II, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW,
Vredenburgh JJ and Rich JN: Tumor angiogenic and hypoxic profiles
predict radiographic response and survival in malignant astrocytoma
patients treated with bevacizumab and irinotecan. J Clin Oncol.
26:271–278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hofstetter CP, Burkhardt JK, Shin BJ,
Gürsel DB, Mubita L, Gorrepati R, Brennan C, Holland EC and
Boockvar JA: Protein phosphatase 2A mediates dormancy of
glioblastoma multiforme-derived tumor stem-like cells during
hypoxia. PLoS One. 7:e300592012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Proescholdt MA, Merrill MJ, Stoerr EM,
Lohmeier A, Pohl F and Brawanski A: Function of carbonic anhydrase
IX in glioblastoma multiforme. Neuro Oncol. 14:1357–1366. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Erpolat OP, Gocun PU, Akmansu M, Ozgun G
and Akyol G: Hypoxia-related molecules HIF-1α, CA9, and
osteopontin: predictors of survival in patients with high-grade
glioma. Strahlenther Onkol. 189:147–154. 2013. View Article : Google Scholar
|
|
47
|
He J, Shan Z, Li L, Liu F, Liu Z, Song M
and Zhu H: Expression of glioma stem cell marker CD133 and
O6-methylguanine-DNA methyltransferase is associated
with resistance to radiotherapy in gliomas. Oncol Rep.
26:1305–1313. 2011.PubMed/NCBI
|
|
48
|
Metellus P, Nanni-Metellus I, Delfino C,
Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M,
Chinot O, et al: Prognostic impact of CD133 mRNA expression in 48
glioblastoma patients treated with concomitant radioche-motherapy:
a prospective patient cohort at a single institution. Ann Surg
Oncol. 18:2937–2945. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nakata S, Campos B, Bageritz J, Bermejo
JL, Becker N, Engel F, Acker T, Momma S, Herold-Mende C, Lichter P,
et al: LGR5 is a marker of poor prognosis in glioblastoma and is
required for survival of brain cancer stem-like cells. Brain
Pathol. 23:60–72. 2013. View Article : Google Scholar
|
|
50
|
Pallini R, Ricci-Vitiani L, Banna GL,
Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G,
Larocca LM, et al: Cancer stem cell analysis and clinical outcome
in patients with glioblastoma multiforme. Clin Cancer Res.
14:8205–8212. 2008. View Article : Google Scholar : PubMed/NCBI
|
